CV NEWS FEED // The National Association of Pro-Life Nurses this week announced that it has joined the Alliance for Hippocratic Medicine in the landmark Supreme Court case against the Food and Drug Administration about the chemical abortion drug mifepristone.
NAPN President Dorothy Kane stated in a news release that the lawsuit “is about safeguarding women’s health, protecting the integrity of the healthcare profession, and committing to evidence-based care.”
Established in 1973, NAPN is a non-profit organization that promotes ethical values in the nursing field and informational resources on bioethical issues.
“Nurses are on the front lines witnessing the serious harms to women caused by the FDA’s reckless removal of essential safeguards for the use of chemical abortion drugs,” Kane stated:
Women deserve the ongoing, in-person care of a medical professional when taking high-risk drugs.
The FDA has compromised patient safety and shown a callous disregard for women’s health and safety.
The Supreme Court of the United States is set to hear oral arguments for the case U.S. Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine on March 26. The plaintiffs argue that the FDA approved the chemical abortion drug mifepristone without sufficient research on its safety and effects.
The plaintiffs also argue that the FDA illegally removed the requirement for in-person doctor visits before receiving a prescription for the chemical abortion drugs. The availability of mifepristone has increased within the last year, as CVS and Walgreens recently announced that they would prescribe the drug via mail or over the counter.
The SCOTUS decision on the case will determine the availability and accessibility of mifepristone.
>> How Bad is Mifepristone For Women? <<
NAPN highlighted that the FDA has disregarded patient safety by removing safeguards despite the drug’s health risks. The FDA also facilitated a lack of informed consent by removing requirements of in-person doctor visits for women seeking an abortion drug regime prescription, NAPN added.
The FDA’s own label for mifepristone and misoprostol states that 1 in 25 women who take the abortion drugs will end up in an emergency room, the NAPN news release noted. Health risks posed by the at-home chemical abortions include incomplete abortions, hemorrhage, and fatal infections.
The post National Association of Pro-Life Nurses joins plaintiffs in lawsuit against FDA on chemical abortion drugs appeared first on CatholicVote org.